PTC Therapeutics: Sephience Keeps Beating The Forecast, But The Price Already Knows

PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.